Giuseppe Vita

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4887417/publications.pdf

Version: 2024-02-01

162 papers	8,685 citations	71102 41 h-index	49909 87 g-index
167 all docs	167 docs citations	167 times ranked	10034 citing authors

#	Article	IF	Citations
1	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 11-21.	27.0	1,944
2	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	27.0	1,000
3	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
4	Ascorbic acid in Charcotâ€“Marieâ€“Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, The, 2011, 10, 320-328.	10.2	222
5	miR-21 and 221 upregulation and miR-181b downregulation in human grade IIâ€“IV astrocytic tumors. Journal of Neuro-Oncology, 2009, 93, 325-332.	2.9	211
6	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2010, 20, 712-716.	0.6	171
7	Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. Sleep Medicine, 2009, 10, 1132-1138.	1.6	152
8	Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 643-649.	0.6	144
9	Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Experimental Neurology, 2006, 198, 234-241.	4.1	128
10	Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nature Medicine, 2014, 20, 992-1000.	30.7	113
11	Lipid Peroxidation Inhibition Blunts Nuclear Factor-ÎºB Activation, Reduces Skeletal Muscle Degeneration, and Enhances Muscle Function in mdx Mice. American Journal of Pathology, 2006, 168, 918-926.	3.8	105
12	Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Skeletal Radiology, 2012, 41, 955-961.	2.0	105
13	Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney International, 1999, 56, 232-237.	5.2	104
14	VEGF overexpression via adenoâ€associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB Journal, 2007, 21, 3737-3746.	0.5	95
15	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	10.2	95
16	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
17	Ictal and interictal EEG abnormalities in ADHD children recorded over night by video-polysomnography. Epilepsy Research, 2007, 75, 130-137.	1.6	90
18	Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. Journal of the Neurological Sciences, 1993, 120, 82-86.	0.6	87

#	Article	IF	Citations
19	Role of Gabapentin in Spinal Muscular Atrophy. Journal of Child Neurology, 2003, 18, 537-541.	1.4	86
20	Nusinersen in type 1 spinal muscular atrophy: Twelveâ€month realâ€world data. Annals of Neurology, 2019, 86, 443-451.	5.3	83
21	Motor function-muscle strength relationship in spinal muscular atrophy. Muscle and Nerve, 2004, 29, 548-552.	2.2	81
22	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81
23	Nuclear factorâ€ÎºB activation and differential expression of survivin and Bclâ€2 in human grade 2â€“4 astrocytomas. Cancer, 2008, 112, 2258-2266.	4.1	70
24	Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area. Journal of Neuromuscular Diseases, 2015, 2, S39-S48.	2.6	67
25	Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. Neuromuscular Disorders, 2018, 28, 582-585.	0.6	67
26	Cardiovascular-Reflex Testing and Single-Fiber Electromyography in Botulism. Archives of Neurology, 1987, 44, 202.	4.5	65
27	The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. European Heart Journal Cardiovascular Imaging, 2014, 15, 1307-1315.	1.2	64
28	Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone. Experimental Neurology, 2009, 220, 349-358.	4.1	58
29	MRI of Cardiac Involvement in Transthyretin Familial Amyloid Polyneuropathy. American Journal of Roentgenology, 2010, 195, W394-W399.	2.2	58
30	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. PLoS ONE, 2015, 10, e0141240.	2.5	58
31	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 2017, 58, 34-39.	1.8	56
32	Endocardial and Epicardial Deformations in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. Circulation Journal, 2011, 75, 1200-1208.	1.6	54
33	RAGE-NF-?B pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta Neurologica Scandinavica, 2007, 115, 115-121.	2.1	53
34	Reduced Adult Neurogenesis and Altered Emotional Behaviors in Autoimmune-Prone B-Cell Activating Factor Transgenic Mice. Biological Psychiatry, 2010, 67, 558-566.	1.3	52
35	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
36	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	2.3	49

#	Article	IF	Citations
37	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research, 2006, 54, 436-441.	7.1	47
38	Cardiovascular autonomic control in Becker muscular dystrophy. Journal of the Neurological Sciences, 2001, 186, 45-49.	0.6	46
39	Oxidative stress in myotonic dystrophy type 1. Free Radical Research, 2005, 39, 771-776.	3.3	45
40	Expression of muscle-specific integrins in masseter muscle fibers during malocclusion disease. International Journal of Molecular Medicine, 2012, 30, 235-242.	4.0	44
41	Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscular Disorders, 2012, 22, 325-330.	0.6	44
42	Increase in Synchronization of Autonomic Rhythms between Individuals When Listening to Music. Frontiers in Physiology, 2017, 8, 785.	2.8	43
43	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
44	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscular Disorders, 2017, 27, 447-451.	0.6	42
45	Transthyretinâ€related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. Journal of the Peripheral Nervous System, 2012, 17, 385-390.	3.1	41
46	MuSK-Associated Myasthenia Gravis: Clinical Features and Management. Frontiers in Neurology, 2020, 11, 660.	2.4	41
47	Uraemic autonomic neuropathy. Journal of the Autonomic Nervous System, 1990, 30, S179-S184.	1.9	39
48	Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases. Neuromuscular Disorders, 2002, 12, 964-969.	0.6	39
49	Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. European Journal of Human Genetics, 2013, 21, 630-636.	2.8	39
50	Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience. Neuromuscular Disorders, 2017, 27, 1084-1086.	0.6	38
51	Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association. Neuromuscular Disorders, 2002, 12, 566-568.	0.6	37
52	Correlation between clinical/neurophysiological findings and quality of life in Charcotâ€Marieâ€Tooth type 1A. Journal of the Peripheral Nervous System, 2008, 13, 64-70.	3.1	37
53	â€œI have got something positive out of this situationâ€: psychological benefits of caregiving in relatives of young people with muscular dystrophy. Journal of Neurology, 2014, 261, 188-195.	3.6	37
54	Hippo signaling pathway is altered in Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0205514.	2.5	37

#	Article	IF	Citations
55	Why do some Friedreich's ataxia patients retain tendon reflexes?. Journal of Neurology, 1999, 246, 353-357.	3.6	36
56	Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. Neuromuscular Disorders, 2009, 19, 223-228.	0.6	36
57	Expression of the tumor necrosis factor receptorâ€"associated factors 1 and 2 and regulation of the nuclear factorâ€"kB antiapoptotic activity in human gliomas. Journal of Neurosurgery, 2005, 103, 873-881.	1.6	35
58	Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle and Nerve, 2015, 52, 13-21.	2.2	35
59	Practical approach to respiratory emergencies in neurological diseases. Neurological Sciences, 2020, 41, 497-508.	1.9	33
60	Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred. , 1996, 19, 1134-1137.		32
61	Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings. Neurological Sciences, 2008, 29, 193-194.	1.9	32
62	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
63	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences, 2019, 40, 661-669.	1.9	32
64	Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. Neuromuscular Disorders, 2005, 15, 409-411.	0.6	31
65	Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy. Neurobiology of Aging, 2011, 32, 2190-2197.	3.1	31
66	The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-Î± activation and ameliorates muscle function and morphology in mdx mice. Neuromuscular Disorders, 2011, 21, 579-589.	0.6	31
67	The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet Journal of Rare Diseases, 2018, 13, 176.	2.7	31
68	Cardiovascular autonomic control in myotonic dystrophy type 1: a correlative study with clinical and genetic data. Neuromuscular Disorders, 2004, 14, 136-141.	0.6	30
69	Expanding the spectrum of genes responsible for hereditary motor neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1171-1179.	1.9	30
70	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. Journal of Medical Genetics, 2019, 56, 293-300.	3.2	30
71	Extra-muscle involvement in dystrophinopathies: an electroretinography and evoked potential study. Journal of the Neurological Sciences, 1997, 146, 127-132.	0.6	27
72	Apoptosis in metabolic myopathies. NeuroReport, 1998, 9, 2431-2435.	1.2	26

#	Article	IF	Citations
73	Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients. Molecular Genetics and Metabolism, 2012, 107, 480-484.	1.1	26
74	Usefulness of Combining Electrocardiographic andÂEchocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects WithÂTransthyretin Gene Mutation. American Journal of Cardiology, 2015, 116, 1122-1127.	1.6	26
75	Expression of cytoskeleton proteins in central core disease. Journal of the Neurological Sciences, 1994, 124, 71-76.	0.6	25
76	Autonomic function in elderly uremics studied by spectral analysis of heart rate. Kidney International, 2005, 67, 1521-1525.	5.2	25
77	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders, 2014, 24, 1003-1017.	0.6	25
78	An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology, 2018, 91, e696-e703.	1.1	24
79	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. Brain Sciences, 2020, 10, 780.	2.3	24
80	Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study. Acta Myologica, 2014, 33, 136-43.	1.5	24
81	Autonomic dysfunction in uremia. American Journal of Kidney Diseases, 2001, 38, S118-S121.	1.9	22
82	Left atrial function in cardiac amyloidosis. Journal of Cardiovascular Medicine, 2016, 17, 113-121.	1.5	21
83	Fetus-like dystrophin expression and other cytoskeletal protein abnormalities in centronuclear myopathies. Muscle and Nerve, 1994, 17, 1176-1184.	2.2	20
84	Endocrine Evaluation for Muscle Pain. Journal of the Royal Society of Medicine, 2001, 94, 405-407.	2.0	20
85	Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. Neuromuscular Disorders, 2009, 19, 44-48.	0.6	20
86	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurological Sciences, 2019, 40, 671-681.	1.9	20
87	Immunolocalization and Activation of Transcription Factor Nuclear Factor ÎºB in Dysimmune Neuropathies and Familial Amyloidotic Polyneuropathy. Archives of Neurology, 2004, 61, 1097-102.	4.5	19
88	Axial myopathy in myasthenia: A misleading cause of dropped head. Muscle and Nerve, 2004, 29, 329-330.	2.2	19
89	Charcotâ€“Marieâ€“Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family. Neurological Sciences, 2015, 36, 1003-1006.	1.9	18
90	Quantitative Comparison Between Amyloid Deposition Detected by ^{99m}Tc-Diphosphonate Imaging and Myocardial Deformation Evaluated by Strain Echocardiography in Transthyretin-Related Cardiac Amyloidosis. Circulation Journal, 2016, 80, 1998-2003.	1.6	18

#	Article	IF	Citations
91	Description of a large cohort of Caucasian patients with <scp>V122I ATTRv</scp> amyloidosis: Neurological and cardiological features. Journal of the Peripheral Nervous System, 2020, 25, 273-278.	3.1	18
92	Evidence of cardiovascular autonomic impairment in mitochondrial disorders. Journal of Neurology, 2007, 254, 1498-1503.	3.6	17
93	Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences, 2021, 11, 545.	2.3	17
94	Expression of Telomeric Repeat Binding Factor-1 in Astroglial Brain Tumors. Neurosurgery, 2005, 56, 802-810.	1.1	16
95	Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. Neurological Sciences, 2020, 41, 1239-1243.	1.9	16
96	Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia, 2005, 60, 806-810.	3.8	15
97	Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscular Disorders, 2005, 15, 259-261.	0.6	15
98	Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart. Neurological Sciences, 2017, 38, 525-526.	1.9	15
99	Chronic migraine in the first COVID-19 lockdown: the impact of sleep, remote working, and other life/psychological changes. Neurological Sciences, 2021, 42, 4403-4418.	1.9	15
100	Immunocytochemistry of muscle cytoskeletal proteins in acid maltase deficiency. Muscle and Nerve, 1994, 17, 655-661.	2.2	14
101	Immunolocalization and activation of nuclear factor-ÎºB in the sciatic nerves of rats with experimental autoimmune neuritis. Journal of Neuroimmunology, 2006, 174, 32-38.	2.3	14
102	Sport activity in Charcotâ€“Marieâ€“Tooth disease: A case study of a Paralympic swimmer. Neuromuscular Disorders, 2016, 26, 614-618.	0.6	14
103	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.6	14
104	Muscle uptake of99mTechnetium pyrophosphate in patients with neuromuscular disorders. Journal of the Neurological Sciences, 1982, 53, 1-7.	0.6	13
105	Specific matrix metalloproteinase expression in focal myositis: an immunopathological study. Acta Neurologica Scandinavica, 2005, 112, 173-177.	2.1	13
106	Unusual features of central nervous system involvement in <scp>CMTX</scp> associated with a novel mutation of <scp>GJB1</scp> gene. Journal of the Peripheral Nervous System, 2012, 17, 407-411.	3.1	13
107	Effectiveness of skeletal scintigraphy in transthyretin-related amyloidosis. International Journal of Cardiology, 2013, 168, 4988-4989.	1.7	13
108	Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscular Disorders, 2016, 26, 374-377.	0.6	13

#	Article	IF	Citations
109	Which are the factors influencing NIV adaptation and tolerance in ALS patients?. Neurological Sciences, 2021, 42, 1023-1029.	1.9	13
110	Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls. Journal of Neuromuscular Diseases, 2016, 3, 413-418.	2.6	12
111	Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 102.	2.9	11
112	Comparison of different techniques for detecting 17p12 duplication in CMT1A. Neuromuscular Disorders, 2005, 15, 488-492.	0.6	10
113	Immunohistochemical analysis of human skeletal muscle AMP deaminase deficiency. Evidence of a correlation between the muscle HPRG content and the level of the residual AMP deaminase activity. Journal of Muscle Research and Cell Motility, 2006, 27, 83-92.	2.0	10
114	Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. Muscle and Nerve, 2012, 45, 451-452.	2.2	10
115	Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice. BioFactors, 2015, 41, 324-329.	5.4	10
116	Congenital muscular dystrophy: Correlation of muscle biopsy and clinical features. Pediatric Neurology, 1994, 10, 233-236.	2.1	9
117	Quantitation of argyrophilic nucleolar organizer regions in regenerating muscle fibers in Duchenne and Becker muscular dystrophies and polymyositis. Acta Neuropathologica, 1999, 97, 247-252.	7.7	9
118	A family with autosomal dominant mutilating neuropathy not linked to either Charcotâ€“Marieâ€“Tooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci. Neuromuscular Disorders, 2002, 12, 286-291.	0.6	9
119	Identification of the infant-type R631C mutation in patients with the benign muscular form of CPT2 deficiency. Neuromuscular Disorders, 2007, 17, 960-963.	0.6	9
120	ANT1 is reduced in sporadic inclusion body myositis. Neurological Sciences, 2013, 34, 217-224.	1.9	9
121	Is it the right time for an infant screening for Duchenne muscular dystrophy?. Neurological Sciences, 2020, 41, 1677-1683.	1.9	9
122	Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences, 2020, 10, 952.	2.3	9
123	A Phase 1/2 Study of Flavocoxid, an Oral NF-ÎºB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences, 2021, 11, 115.	2.3	9
124	Effect of exercise on telomere length and telomere proteins expression in mdx mice. Molecular and Cellular Biochemistry, 2020, 470, 189-197.	3.1	9
125	Psychosocial impact of sport activity in neuromuscular disorders. Neurological Sciences, 2020, 41, 2561-2567.	1.9	8
126	Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. Brain Sciences, 2021, 11, 515.	2.3	8

#	Article	IF	Citations
127	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	2.7	8
128	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiology and Therapy, 2021, 10, 481-490.	2.6	8
129	Perineurium talin immunoreactivity decreases in diabetic neuropathy. Journal of the Neurological Sciences, 1997, 146, 7-11.	0.6	7
130	Dp116, talin, vinculin and vimentin immunoreactivities following nerve transection. NeuroReport, 1998, 9, 697-702.	1.2	7
131	Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD). Frontiers in Neurology, 2018, 9, 880.	2.4	7
132	Socio-Economic Factors, Food Habits and Phosphorus Levels in Patients on Hemodialysis. Nephro-Urology Monthly, 2015, 7, e27114.	0.1	7
133	Autonomic Involvement in Subacute and Chronic Immune-Mediated Neuropathies. Autoimmune Diseases, 2013, 2013, 1-7.	0.6	6
134	Are novel outcome measures for Charcotâ€“Marieâ€“Tooth disease sensitive to change? The 6-minute walk test and StepWatchâ„¢ Activity Monitor in a 12-month longitudinal study. Neuromuscular Disorders, 2019, 29, 310-316.	0.6	6
135	Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs. Acta Myologica, 2017, 36, 41-45.	1.5	6
136	Letters to the Editor. Muscle and Nerve, 1996, 19, 926-931.	2.2	5
137	Apoptosis and apoptosis-related proteins in thyroid myopathies. Muscle and Nerve, 2002, 26, 383-388.	2.2	5
138	Calpain 3 deficiency in Quail Eater's disease. Annals of Neurology, 2004, 55, 146-147.	5.3	5
139	A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript â€œsingle-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1â€• written by pechmann and colleaguesâ€• European Journal of Paediatric Neurology, 2018, 22, 729-731.	1.6	5
140	Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center. Neurological Sciences, 2018, 39, 1961-1964.	1.9	5
141	Early impairment of right ventricular morphology and function in transthyretin-related cardiac amyloidosis. Journal of Cardiovascular Echography, 2021, 31, 17.	0.4	5
142	Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates. Journal of Endocrinological Investigation, 2022, 45, 517-525.	3.3	5
143	Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 197-204.	3.0	5
144	Localization of vinculin and talin at perineurial cells of human sural nerve. NeuroReport, 1995, 6, 2077-2080.	1.2	4

#	Article	IF	Citations
145	Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study. Journal of the Neurological Sciences, 2006, 246, 31-35.	0.6	4
146	Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies. Acta Neurologica Scandinavica, 2007, 117, 393-398.	2.1	4
147	Novel SHOX Gene Mutation in a Short Boy with Becker Muscular Dystrophy: Double Trouble in Two Adjacent Genes. Hormone Research in Paediatrics, 2008, 69, 124-128.	1.8	4
148	Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions. Acta Myologica, 2017, 36, 19-24.	1.5	4
149	Osteosclerotic Myeloma With Spinal Leptomeningitis and Severe Polyneuropathy. Journal of Computer Assisted Tomography, 2006, 30, 649-652.	0.9	3
150	Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers. Clinical and Translational Imaging, 2017, 5, 545-559.	2.1	3
151	Unilateral hyperhidrosis as persistently isolated feature of syringomyelia and Arnold Chiari type 1. Neurological Sciences, 2018, 39, 1607-1608.	1.9	3
152	From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 279-280.	3.0	3
153	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy. Scientific Reports, 2021, 11, 9216.	3.3	3
154	Have Duchenne Muscular Dystrophy Patients an Increased Cancer Risk?. Journal of Neuromuscular Diseases, 2021, 8, 1063-1067.	2.6	3
155	Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance. Acta Myologica, 2020, 39, 191-199.	1.5	3
156	The 6-min walk test as a new outcome measure in Amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 15580.	3.3	2
157	Letter to the editor. Muscle and Nerve, 1995, 18, 251-257.	2.2	1
158	Agenesis of the Internal Carotid Artery Associated with Generalized Epilepsy. Journal of Clinical		